Please check your internet connection and try again.
# Sompraz HP
## Overview
Sompraz HP is a prescription "Helicobacter pylori kit" (or "H. pylori packing") containing a combination of **Esomeprazole** (a proton pump inhibitor), **Amoxicillin** (a penicillin antibiotic), and **Clarithromycin** (a macrolide antibiotic). It is designed as a 7- to 14-day therapeutic regimen to eradicate *H. pylori* and treat associated peptic ulcer disease.
## Primary Indications
Treatment of *Helicobacter pylori* infection in patients with duodenal ulcers or chronic gastritis to reduce the risk of ulcer recurrence.
## Adult Dosing
Standard regimen (varies by local product labeling, usually taken twice daily):
* **Esomeprazole:** 20 mg or 40 mg twice daily.
* **Amoxicillin:** 1000 mg twice daily.
* **Clarithromycin:** 500 mg twice daily.
* **Duration:** Typically 7 to 14 days based on regional antibiotic resistance patterns and local guidelines.
## Pediatric Dosing
**Not established.** Safety and efficacy of this specific triple-therapy combination kit have not been formally established in pediatric patients. Use in children should be deferred to pediatric infectious disease specialists or gastroenterologists.
## Dose Adjustments
* **Renal Impairment:** Amoxicillin requires adjustment if CrCl < 30 mL/min. Consultation is mandatory; usually, the frequency of amoxicillin is decreased.
* **Hepatic Impairment:** Use with caution. Dosage of Esomeprazole may need to be capped (e.g., 20 mg/day) in severe hepatic impairment (Child-Pugh C).
## Contraindications
* Known hypersensitivity to esomeprazole, amoxicillin, clarithromycin, or any other macrolide or beta-lactam antibiotic.
* Concomitant use with drugs known to interact severely with clarithromycin (e.g., cisapride, pimozide, astemizole, terfenadine, ergot derivatives, or HMG-CoA reductase inhibitors extensively metabolized by CYP3A4, such as lovastatin or simvastatin).
## Adverse Effects
* **Common:** Diarrhea, dysgeusia (metallic taste), nausea, abdominal pain, and headache.
* **Serious:** *Clostridioides difficile*-associated diarrhea (CDAD), severe hypersensitivity reactions (anaphylaxis, DRESS syndrome), QT prolongation (clarithromycin), and increased risk of *Salmonella/Campylobacter* infections due to gastric acid suppression.
## Key Drug Interactions
* **CYP3A4 substrates:** Clarithromycin is a potent inhibitor; can significantly increase serum levels of drugs like carbamazepine, ciclosporin, and colchicine.
* **Warfarin:** Monitor INR closely; both PPIs and macrolides may enhance anticoagulant effect.
* **pH-dependent drugs:** Esomeprazole may decrease absorption of atazanavir, ketoconazole, and mycophenolate mofetil.
## Monitoring
* Monitor for signs of *C. difficile* (persistent watery diarrhea).
* Assess for clinical signs of hypersensitivity (rash, urticaria, wheezing).
* Monitor hepatic function if therapy exceeds 14 days (rare for this indication).
* Verify eradication via urea breath test or fecal antigen test 4 weeks after therapy completion.
## Clinical Pearls
* **Resistance:** Due to rising clarithromycin resistance, this regimen may fail in many regions. Local sensitivity patterns must guide therapy.
* **Adherence:** Patients must complete the full course to prevent secondary bacterial resistance.
* **Timing:** Take at least 60 minutes before a meal for optimal PPI efficacy.
* **Clarithromycin Taste:** Patients often report a bitter or metallic taste; advise that this is a known side effect that resolves after stopping the drug.
***
**Disclaimer:** This information is for educational purposes only. Drug information, regional resistance patterns, and clinical guidelines change frequently. Always consult the most recent product monograph and local institutional protocols before prescribing or administering medication.
